TY - JOUR
T1 - Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas
AU - Palomero, Teresa
AU - Couronné, Lucile
AU - Khiabanian, Hossein
AU - Kim, Mi Yeon
AU - Ambesi-Impiombato, Alberto
AU - Perez-Garcia, Arianne
AU - Carpenter, Zachary
AU - Abate, Francesco
AU - Allegretta, Maddalena
AU - Haydu, J. Erika
AU - Jiang, Xiaoyu
AU - Lossos, Izidore S.
AU - Nicolas, Concha
AU - Balbin, Milagros
AU - Bastard, Christian
AU - Bhagat, Govind
AU - Piris, Miguel A.
AU - Campo, Elias
AU - Bernard, Olivier A.
AU - Rabadan, Raul
AU - Ferrando, Adolfo A.
N1 - Funding Information:
We would like to thank V. Ribrag (Institut Gustave Roussy) for providing a PTCL sample and R. Parsons (Mount Sinai School of Medicine) for assistance in the setup of RHOA GTP-loading assays. This work was supported by a Leukemia and Lymphoma Society Translational Research Grant (A.A.F.), a Herbert Irving Comprehensive Cancer Center interprogrammatic pilot project grant (A.A.F. and R.R.), a US National Institutes of Health Ruth L. Kirschstein National Research Service Award (1F30CA174099 to J.E.H.), a grant from the Ligue Nationale Contre le Cancer (O.A.B.) and an Institut National du Cancer (INCa)–Direction de l’Hospitalisation et de l’Organisation des soins (DHOS) translational research grant (O.A.B.). L.C. is funded by ITMO (Institut Multi-Organismes Cancer) and INCa. M.-Y.K. is funded by the Leukemia and Lymphoma Society. E.C. is supported by the Spanish Ministry of Science and Innovation (SAF2012-38432) and Institucio Catalana de Recerca i Estudis Avancats.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Peripheral T cell lymphomas (PTCLs) are a heterogeneous and poorly understood group of non-Hodgkin lymphomas. Here we combined whole-exome sequencing of 12 tumor-normal DNA pairs, RNA sequencing analysis and targeted deep sequencing to identify new genetic alterations in PTCL transformation. These analyses identified highly recurrent epigenetic factor mutations in TET2, DNMT3A and IDH2 as well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) PTCL, not otherwise specified (PTCL-NOS) samples. Mechanistically, the RHOA Gly17Val protein interferes with RHOA signaling in biochemical and cellular assays, an effect potentially mediated by the sequestration of activated guanine-exchange factor (GEF) proteins. In addition, we describe new and recurrent, albeit less frequent, genetic defects including mutations in FYN, ATM, B2M and CD58 implicating SRC signaling, impaired DNA damage response and escape from immune surveillance mechanisms in the pathogenesis of PTCL.
AB - Peripheral T cell lymphomas (PTCLs) are a heterogeneous and poorly understood group of non-Hodgkin lymphomas. Here we combined whole-exome sequencing of 12 tumor-normal DNA pairs, RNA sequencing analysis and targeted deep sequencing to identify new genetic alterations in PTCL transformation. These analyses identified highly recurrent epigenetic factor mutations in TET2, DNMT3A and IDH2 as well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) PTCL, not otherwise specified (PTCL-NOS) samples. Mechanistically, the RHOA Gly17Val protein interferes with RHOA signaling in biochemical and cellular assays, an effect potentially mediated by the sequestration of activated guanine-exchange factor (GEF) proteins. In addition, we describe new and recurrent, albeit less frequent, genetic defects including mutations in FYN, ATM, B2M and CD58 implicating SRC signaling, impaired DNA damage response and escape from immune surveillance mechanisms in the pathogenesis of PTCL.
UR - http://www.scopus.com/inward/record.url?scp=84895829862&partnerID=8YFLogxK
U2 - 10.1038/ng.2873
DO - 10.1038/ng.2873
M3 - Article
C2 - 24413734
AN - SCOPUS:84895829862
SN - 1061-4036
VL - 46
SP - 166
EP - 170
JO - Nature Genetics
JF - Nature Genetics
IS - 2
ER -